Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01237301 · ClinicalTrials.gov registry record · NA

Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes

A NA study, sponsored by HealthPartners Institute.

Completed
Registry status
NA
Development phase
124
Enrollment target

NCT01237301: Completed NA study, sponsored by HealthPartners Institute.

NCT01237301 is a NA study that has completed, run by HealthPartners Institute. The registered enrollment target is 124 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01237301, a NA study, has completed, sponsored by HealthPartners Institute.

COMPLETED
Registry status
NA
Development phase
124 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the use of SMBG and CGM for clinical decisions related to the management of type 2 diabetes. The secondary objective is to determine the benefit of using CGM for clinical diabetes management decision-making.

Interventions

  • DEVICE CGM Group
  • DEVICE SMBG Group

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2010-10
Est. Completion 2012-03
Phase NA
HealthPartners Institute

146 total trials

What the finished NCT01237301 record still lists

NCT01237301 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 2 interventions - of which CGM Group is the first listed.

NCT01237301 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01237301 about?

NCT01237301 is a clinical study titled "Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes". The purpose of this study is to evaluate the use of SMBG and CGM for clinical decisions related to the management of type 2 diabetes. The secondary objective is to determine the benefit of using CGM for clinical diabetes management decision-making.

What is the current status of trial NCT01237301?

This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2010-10. Estimated completion is 2012-03.

What interventions are being tested in trial NCT01237301?

The interventions under investigation include: CGM Group (DEVICE), SMBG Group (DEVICE).

Who is sponsoring clinical trial NCT01237301?

This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01237301's enrollment target sits among peer trials

124 758th of 2000 higher than 1,239 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523014 · 124 participants · Phase 2

    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • NCT02670707 · 124 participants · Phase 3

    Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

  • NCT02830724 · 124 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • NCT04748809 · 124 participants · NA

    Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01237301, the US trial registry maintained by the National Library of Medicine. NCT01237301 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.